ConductScience.org, home
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
API referenceFor AI assistants

Trial · NCT01124864

Results by group48

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 48

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Response Assessment by Study Stratum - Per Investigator AssessmentKras Mutant PatientsOverall respose rate (ORR)0Participants
Response Assessment by Study Stratum - Per Investigator AssessmentEGFR Mutant PatientsOverall respose rate (ORR)6Participants
Response Assessment by Study Stratum - Per Investigator AssessmentEGFR and Kras Wild Type PatientsOverall respose rate (ORR)3Participants
Response Assessment by Study Stratum - Per Investigator AssessmentPatients With EML4-ALK TranslocationOverall respose rate (ORR)7Participants
Response Assessment by Study Stratum - Per Investigator AssessmentModified EGFR Mutant PatientsOverall respose rate (ORR)3Participants
Response Assessment by Study Stratum - Per Investigator AssessmentUnknownOverall respose rate (ORR)1Participants
Response Assessment by Study Stratum - Per Investigator AssessmentKras Mutant PatientsStable disease for ≥18 weeks2Participants
Response Assessment by Study Stratum - Per Investigator AssessmentEGFR Mutant PatientsStable disease for ≥18 weeks3Participants
Response Assessment by Study Stratum - Per Investigator AssessmentEGFR and Kras Wild Type PatientsStable disease for ≥18 weeks3Participants
Response Assessment by Study Stratum - Per Investigator AssessmentPatients With EML4-ALK TranslocationStable disease for ≥18 weeks2Participants
Response Assessment by Study Stratum - Per Investigator AssessmentModified EGFR Mutant PatientsStable disease for ≥18 weeks7Participants
Response Assessment by Study Stratum - Per Investigator AssessmentUnknownStable disease for ≥18 weeks0Participants
Response Assessment by Study Stratum - Per Investigator AssessmentKras Mutant PatientsNo clinical benefit26Participants
Response Assessment by Study Stratum - Per Investigator AssessmentEGFR Mutant PatientsNo clinical benefit26Participants
Response Assessment by Study Stratum - Per Investigator AssessmentEGFR and Kras Wild Type PatientsNo clinical benefit28Participants
Response Assessment by Study Stratum - Per Investigator AssessmentPatients With EML4-ALK TranslocationNo clinical benefit13Participants
Response Assessment by Study Stratum - Per Investigator AssessmentModified EGFR Mutant PatientsNo clinical benefit21Participants
Response Assessment by Study Stratum - Per Investigator AssessmentUnknownNo clinical benefit2Participants
Overall Survival Rate Using Kaplan Meier Estimates - Per Investigator Radiological ReviewKras Mutant Patients12 weeks68.747.0 to 83.0Percentage of participants
Overall Survival Rate Using Kaplan Meier Estimates - Per Investigator Radiological ReviewEGFR Mutant Patients12 weeks77.059.3 to 8708Percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01124864/results

API referenceFor AI assistants